Table 2.
PTEN loss and clinical outcome of panitumumab- or cetuximab-based treatment in wild-type KRAS patients with colorectal cancer
| References | Year | Regimen | Design | Expression/loss | OS | PFS/TTP | OR (%) |
|---|---|---|---|---|---|---|---|
| Laurent-Puig et al9 | 2009 | CTX + chemotherapy | RCo | 89/22 | 16.2 vs 11.8 m P=0.013# 15.1 vs 13.1 m |
PFS: 31.4 vs 30 w P=0.275# PFS: 5.3 vs 3.7 m |
NA |
| Loupakis et al26 | 2009 | CTX + chemotherapy | RCo | 17/10 | HR=0.50 P=0.127# 14.5 vs 15.3 m |
HR=0.45 P=0.026# TTP: 5.0 vs 3.7 m |
NA |
| Saridaki et al55 | 2011 | CTX + chemotherapy | RCo | 60/14 | HR=1.1 P=0.862 69.2 vs 36.9 w |
HR=2.7 P=0.002 PFS: 24.4 vs 15.7 w |
NA |
| Sood et al32 | 2012 | CTX/Pani ± chemotherapy | RCo | NA | HR=0.339 P=0.0015 15.1 vs 9.9 m |
HR=0.65 P=0.258 PFS: 14 vs 5 m |
NA 42% vs 12% |
| Tural et al56 | 2014 | CTX + chemotherapy | RCo | 26/15 | HR=0.34 P=0.008 |
HR=0.4 P=0.028 |
P=0.04 |
| Razis et al54 | 2014 | CTX ± chemotherapy | RCo | 59/80 | TTP: 9.5 vs 6.1 m P=0.019 |
NA |
Note:
#
Log-rank test.
Abbreviations: CTX, cetuximab; Pani, panitumumab; RCo, retrospective cohort study; NA, date not available; HR, hazard ratio; PFS, progression-free survival; TTP, time to progression; m, months; w, weeks; OS, overall survival; OR, odds ratio.